~~Claims:~~

~~1. An RNAi agent for inhibiting expression of a Hepatitis B Virus gene comprising an antisense strand and a sense strand, wherein the antisense strand comprises a sequence having at least about 85% identity to any of the antisense strand sequences provided in Table 2 or Table 3.~~

~~2. The RNAi agent of claim 1, wherein the antisense strand comprises at least 16 contiguous nucleotides of any of the antisense sequences provided in Table 2 or Table 3.~~

~~3. The composition of claim 1, wherein the antisense strand comprises the nucleotides at positions 2 through 18 (5′→3′) of any of the antisense strand sequences provided in Table 2 or Table 3.~~

~~4. The RNAi agent of claim 1 or claim 2, wherein at least one nucleotide of the sense strand and/or at least one nucleotide of the antisense strand of the RNAi agent is a modified nucleotide and/or has a modified internucleoside linkage.~~

~~5. The RNAi agent of any of claims 1-4, wherein the sense strand and the antisense strand are each 17 to 30 nucleotides in length.~~

~~6. The RNAi agent of any of claims 1-5, wherein the sense strand comprises at least 16 contiguous nucleotides of any of the sense strand sequences provided in Table 2 or Table 4, and wherein the sense strand has a region of at least about 85% complementarity over the contiguous 16 nucleotides to the antisense strand.~~

~~7. The RNAi agent of any of claims 1-6, wherein all or substantially all of the nucleotides in both the sense strand and the antisense strand of the RNAi agent are modified nucleotides.~~

~~8. The RNAi agent of claim 1, wherein the antisense strand comprises the nucleotide sequence of any of the modified sequences provided in Table 3.~~

~~9. The RNAi agent of claim 1 or claim 8, wherein the sense strand comprises the nucleotide sequence of any of the modified sense sequences provided in Table 4.~~

~~10. A composition for inhibiting the expression of a HBV gene comprising an RNAi agent of any of claims 1-9, wherein the RNAi agent is conjugated to a targeting ligand.~~

~~11. The composition of claim 10, wherein the targeting ligand comprises N-acetyl-galactosamine.~~

~~12. The composition of claim 11, wherein the targeting ligand is (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s,~~

(NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), or (NAG39)s.

13. The composition of any of claims 10-12, wherein the targeting ligand is conjugated to the sense strand of the RNAi agent.

14. The composition of any of claims 10-13, wherein the composition further comprises a pharmaceutically acceptable excipient.

15. The composition of any of claims 10-14, wherein the RNAi agent has the duplex structure of AD03498; AD03499; AD03500; AD03501; AD03738; AD03739; AD03967; AD03968; AD03969; AD03970; AD03971; AD03972; AD03973; AD03974; AD03975; AD03976; AD03977; AD03978; AD04001; AD04002; AD04003; AD04004; AD04005; AD04006; AD04007; AD04008; AD04009; AD04010; AD04176; AD04177; AD04178; AD04412; AD04413; AD04414; AD04415; AD04416; AD04417; AD04418; AD04419; AD04420; AD04421; AD04422; AD04423; AD04425; AD04426; AD04427; AD04428; AD04429; AD04430; AD04431; AD04432; AD04433; AD04434; AD04435; AD04436; AD04437; AD04438; AD04439; AD04440; AD04441; AD04442; AD04511; AD04570; AD04571; AD04572; AD04573; AD04574; AD04575; AD04576; AD04577; AD04578; AD04579; AD04580; AD04581; AD04583; AD04584; AD04585; AD04586; AD04587; AD04588; AD04590; AD04591; AD04592; AD04593; AD04594; AD04595; AD04596; AD04597; AD04598; AD04599; AD04734; AD04771; AD04772; AD04773; AD04774; AD04775; AD04776; AD04777; AD04778; AD04822; AD04823; AD04871; AD04872; AD04873; AD04874; AD04875; AD04876; AD04881; AD04882; AD04883; AD04884; AD04885; AD04962; AD04963; AD04981; AD04982; AD04983; AD05069; AD05070; AD05071; AD05072; AD05073; AD05074; AD05075; AD05076; AD05077; AD05078; AD05147; AD05148; AD05149; AD05164; or AD05165.

16. The composition of claim 15, wherein the RNAi agent has the duplex structure of AD04580; AD04585; AD04776; AD04872; AD04962; AD04963; AD04982; or AD05070.

17. The composition of any of claims 10-16, wherein the composition further comprises a second RNAi agent comprising a sense strand and an antisense strand for inhibiting expression of a Hepatitis B Virus gene.

18. The composition of claim 17, wherein the second RNAi agent comprises an antisense sequence having at least about 85% identity to any of the antisense strand sequences provided in Table 2 or Table 3.

19. The composition of claim 18, wherein the antisense strand of the second RNAi agent comprises at least 16 contiguous nucleotides of any of the antisense sequences provided in Table 2 or Table 3.

20. The composition of claim 19, wherein the antisense strand of the second RNAi agent comprises the nucleotides at positions 2 through 18 (5′→3′) of any of the antisense strand sequences provided in Table 2 or Table 3.

21. The composition of any of claims 17-20, wherein the first RNAi agent targets the S open reading frame (ORF) of an HBV gene, and the second RNAi agent targets the X open reading frame (ORF) of an HBV gene.

22. The composition of any of claims 17-20, wherein the first RNAi agent targets the X ORF of an HBV gene, and the second RNAi agent targets the S ORF of an HBV gene.

23. The composition of any of claims 17-21, wherein the first RNAi agent is selected from the group consisting of: AD04001; AD04002; AD04003; AD04004; AD04005; AD04006; AD04007; AD04008; AD04009; AD04010; AD04422; AD04423; AD04425; AD04426; AD04427; AD04428; AD04429; AD04430; AD04431; AD04432; AD04433; AD04434; AD04435; AD04436; AD04437; AD04438; AD04439; AD04440; AD04441; AD04442; AD04511; AD04581; AD04583; AD04584; AD04585; AD04586; AD04587; AD04588; AD04590; AD04591; AD04592; AD04593; AD04594; AD04595; AD04596; AD04597; AD04598; AD04599; AD04734; AD04771; AD04772; AD04773; AD04774; AD04775; AD04822; AD04871; AD04872; AD04873; AD04874; AD04875; AD04876; AD04962; and AD05164; and the second RNAi agent is selected from the group consisting of: AD03498; AD03499; AD03500; AD03501; AD03738; AD03739; AD03967; AD03968; AD03969; AD03970; AD03971; AD03972; AD03973; AD03974; AD03975; AD03976; AD03977; AD03978; AD04176; AD04177; AD04178; AD04412; AD04413; AD04414; AD04415; AD04416; AD04417; AD04418; AD04419; AD04420; AD04421; AD04570; AD04571; AD04572; AD04573; AD04574; AD04575; AD04576; AD04577; AD04578; AD04579; AD04580; AD04776; AD04777; AD04778; AD04823; AD04881; AD04882; AD04883; AD04884; AD04885; AD04963; AD04981; AD04982; AD04983; AD05069; AD05070; AD05071; AD05072; AD05073; AD05074; AD05075; AD05076; AD05077; AD05078; AD05147; AD05148; AD05149; and AD05165.

24. The composition of any of claims 17-21 or 23, wherein the first RNAi agent is AD04872 and the second RNAi agent is AD05070.

25. The composition of any of claims 17-21 or 23, wherein the first RNAi agent is AD04872 and the second RNAi agent is AD04982.

26. The composition of any of claims 17-21 or 23, wherein the first RNAi agent is AD04872 and the second RNAi agent is AD04776.

27. The composition of any of claims 17-21, wherein the first RNAi agent is AD04585 and the second RNAi agent is AD04580.

28. The composition of any of claims 10-27, further comprising one or more additional therapeutics.

29. The composition of claim 28, wherein the additional therapeutic is lamivudine, tenofovir, tenofovir alafenamide, tenofovir disoproxil, or entecavir.

30. The composition of claim 28, wherein the additional therapeutic is interferon.

31. A method for inhibiting expression of a Hepatitis B Virus gene in a subject, comprising administering to the subject the RNAi agent of any of claims 1-9.

32. A method for inhibiting expression of a Hepatitis B Virus gene in a subject, comprising administering to the subject the composition of any of claims 10-30.

33. The method of claim 31 or claim 32, wherein the subject has or is at risk of having an HBV infection.

34. A method for treating HBV infection and/or a disease, disorder, or condition associated with HBV infection in a subject, comprising administering to a subject an effective amount of the RNAi agent of any of claims 1-9.

35. A method for treating HBV infection and/or a disease, disorder, or condition associated with HBV infection in a subject, comprising administering to a subject an effective amount of the composition of any of claims 10-30.

36. The method of claim 32, 33, or 35, wherein the composition comprises an effective amount of two RNAi agents for inhibiting the expression of a Hepatitis B Virus gene.

37. The method of any of any of claims 32, 33, 35, or 36, wherein the effective amount of the composition is sufficient to reduce the level of HBsAg in a subject by at least about 40% relative to the subject's HBsAg expression level prior to administration of the composition.

38. The method of any of any of claims 32, 33, 35, or 36, wherein the effective amount of the composition is sufficient to reduce the level of HBeAg in a subject by at least about

40% relative to the subject's HBeAg expression level prior to administration of the composition.

39. The method of any of any of claims 32, 33, 35, or 36, wherein the effective amount of the composition is sufficient to reduce the serum HBV DNA level in a subject by at least about 40% relative to the subject's serum HBV DNA level prior to administration of the composition.

40. The method of claims 34 or 35, wherein the disease, disorder, or condition associated with HBV infection is a chronic liver disease or disorder, liver inflammation, fibrotic condition, a proliferative disorder, hepatocellular carcinoma, Hepatitis D virus infection, or acute HBV infection.

41. The method of any of claims 32, 33, 35, 36, 37, 38, 39, or 40, wherein the first RNAi agent and the second RNAi agent are administered in a ratio of about 1:1.

42. The method of any of claims 32, 33, 35, 36, 37, 38, 39, or 40, wherein the first RNAi agent and the second RNAi agent are administered in a ratio of about 2:1.

43. The method of any of claims 32, 33, 35, 36, 37, 38, 39, or 40, wherein the first RNAi agent and the second RNAi agent are administered in a ratio of about 3:1.

44. The method of any of claims 32, 33, 35, 36, 37, 38, 39, or 40, wherein the first RNAi agent and the second RNAi agent are administered in a ratio of about 4:1.

45. The method of any of claims 32, 33, 35, 36, 37, 38, 39, or 40, wherein the first RNAi agent and the second RNAi agent are administered in a ratio of about 5:1.

46. The method of any of claims 32, 33, 35, 36, 37, 38, 39, or 40, wherein the effective amount of the first RNAi agent is between about 0.5 mg/kg and about 5 mg/kg, and the effective amount of the second RNAi agent is between about 0.5 mg/kg and about 5 mg/kg.

47. The method of claim 31, wherein the effective amount of the RNAi agent is between about 0.5 mg/kg and about 5 mg/kg.

48. Use of the RNAi agent of any of claims 1-9 for the treatment of HBV infection.

49. Use of the composition of any of claims 10-30 for the treatment of HBV infection.

50. Use of the composition of any of claims 10-30 for the manufacture of a medicament for treatment of HBV infection.

51. An RNAi agent for inhibiting expression of a Hepatitis B Virus gene comprising an antisense strand and a sense strand, wherein the RNAi agent has a duplex structure comprising a sense strand or an antisense strand that is identical or substantially identical

to the respective sense or antisense strand in the duplex structure from the group consisting of: AD03498; AD03499; AD03500; AD03501; AD03738; AD03739; AD03967; AD03968; AD03969; AD03970; AD03971; AD03972; AD03973; AD03974; AD03975; AD03976; AD03977; AD03978; AD04001; AD04002; AD04003; AD04004; AD04005; AD04006; AD04007; AD04008; AD04009; AD04010; AD04176; AD04177; AD04178; AD04412; AD04413; AD04414; AD04415; AD04416; AD04417; AD04418; AD04419; AD04420; AD04421; AD04422; AD04423; AD04425; AD04426; AD04427; AD04428; AD04429; AD04430; AD04431; AD04432; AD04433; AD04434; AD04435; AD04436; AD04437; AD04438; AD04439; AD04440; AD04441; AD04442; AD04511; AD04570; AD04571; AD04572; AD04573; AD04574; AD04575; AD04576; AD04577; AD04578; AD04579; AD04580; AD04581; AD04583; AD04584; AD04585; AD04586; AD04587; AD04588; AD04590; AD04591; AD04592; AD04593; AD04594; AD04595; AD04596; AD04597; AD04598; AD04599; AD04734; AD04771; AD04772; AD04773; AD04774; AD04775; AD04776; AD04777; AD04778; AD04822; AD04823; AD04871; AD04872; AD04873; AD04874; AD04875; AD04876; AD04881; AD04882; AD04883; AD04884; AD04885; AD04962; AD04963; AD04981; AD04982; AD04983; AD05069; AD05070; AD05071; AD05072; AD05073; AD05074; AD05075; AD05076; AD05077; AD05078; AD05147; AD05148; AD05149; AD05164; or AD05165.

52. The RNAi agent of claim 51, wherein the RNAi agent has a duplex structure comprising a sense strand that is identical or substantially identical to the respective sense in the duplex structure from the group consisting of: AD03498; AD03499; AD03500; AD03501; AD03738; AD03739; AD03967; AD03968; AD03969; AD03970; AD03971; AD03972; AD03973; AD03974; AD03975; AD03976; AD03977; AD03978; AD04001; AD04002; AD04003; AD04004; AD04005; AD04006; AD04007; AD04008; AD04009; AD04010; AD04176; AD04177; AD04178; AD04412; AD04413; AD04414; AD04415; AD04416; AD04417; AD04418; AD04419; AD04420; AD04421; AD04422; AD04423; AD04425; AD04426; AD04427; AD04428; AD04429; AD04430; AD04431; AD04432; AD04433; AD04434; AD04435; AD04436; AD04437; AD04438; AD04439; AD04440; AD04441; AD04442; AD04511; AD04570; AD04571; AD04572; AD04573; AD04574; AD04575; AD04576; AD04577; AD04578; AD04579; AD04580; AD04581; AD04583; AD04584; AD04585; AD04586; AD04587; AD04588; AD04590; AD04591; AD04592; AD04593; AD04594; AD04595; AD04596; AD04597; AD04598; AD04599; AD04734; AD04771; AD04772; AD04773; AD04774; AD04775; AD04776; AD04777; AD04778;

AD04822; AD04823; AD04871; AD04872; AD04873; AD04874; AD04875; AD04876; AD04881; AD04882; AD04883; AD04884; AD04885; AD04962; AD04963; AD04981; AD04982; AD04983; AD05069; AD05070; AD05071; AD05072; AD05073; AD05074; AD05075; AD05076; AD05077; AD05078; AD05147; AD05148; AD05149; AD05164; or AD05165.

53. The RNAi agent of claim 52, wherein the RNAi agent has a duplex structure comprising an antisense strand that is identical or substantially identical to the respective antisense strand in the duplex structure from the group consisting of: AD03498; AD03499; AD03500; AD03501; AD03738; AD03739; AD03967; AD03968; AD03969; AD03970; AD03971; AD03972; AD03973; AD03974; AD03975; AD03976; AD03977; AD03978; AD04001; AD04002; AD04003; AD04004; AD04005; AD04006; AD04007; AD04008; AD04009; AD04010; AD04176; AD04177; AD04178; AD04412; AD04413; AD04414; AD04415; AD04416; AD04417; AD04418; AD04419; AD04420; AD04421; AD04422; AD04423; AD04425; AD04426; AD04427; AD04428; AD04429; AD04430; AD04431; AD04432; AD04433; AD04434; AD04435; AD04436; AD04437; AD04438; AD04439; AD04440; AD04441; AD04442; AD04511; AD04570; AD04571; AD04572; AD04573; AD04574; AD04575; AD04576; AD04577; AD04578; AD04579; AD04580; AD04581; AD04583; AD04584; AD04585; AD04586; AD04587; AD04588; AD04590; AD04591; AD04592; AD04593; AD04594; AD04595; AD04596; AD04597; AD04598; AD04599; AD04734; AD04771; AD04772; AD04773; AD04774; AD04775; AD04776; AD04777; AD04778; AD04822; AD04823; AD04871; AD04872; AD04873; AD04874; AD04875; AD04876; AD04881; AD04882; AD04883; AD04884; AD04885; AD04962; AD04963; AD04981; AD04982; AD04983; AD05069; AD05070; AD05071; AD05072; AD05073; AD05074; AD05075; AD05076; AD05077; AD05078; AD05147; AD05148; AD05149; AD05164; or AD05165.

54. The RNAi agent of claim 53, wherein the RNAi agent has a duplex structure comprising a sense strand and an antisense strand that are both identical or substantially identical to the respective sense and antisense strand in the duplex structure from the group consisting of: AD03498; AD03499; AD03500; AD03501; AD03738; AD03739; AD03967; AD03968; AD03969; AD03970; AD03971; AD03972; AD03973; AD03974; AD03975; AD03976; AD03977; AD03978; AD04001; AD04002; AD04003; AD04004; AD04005; AD04006; AD04007; AD04008; AD04009; AD04010; AD04176; AD04177; AD04178; AD04412; AD04413; AD04414; AD04415; AD04416; AD04417; AD04418; AD04419;

~~AD04420; AD04421; AD04422; AD04423; AD04425; AD04426; AD04427; AD04428; AD04429; AD04430; AD04431; AD04432; AD04433; AD04434; AD04435; AD04436; AD04437; AD04438; AD04439; AD04440; AD04441; AD04442; AD04511; AD04570; AD04571; AD04572; AD04573; AD04574; AD04575; AD04576; AD04577; AD04578; AD04579; AD04580; AD04581; AD04583; AD04584; AD04585; AD04586; AD04587; AD04588; AD04590; AD04591; AD04592; AD04593; AD04594; AD04595; AD04596; AD04597; AD04598; AD04599; AD04734; AD04771; AD04772; AD04773; AD04774; AD04775; AD04776; AD04777; AD04778; AD04822; AD04823; AD04871; AD04872; AD04873; AD04874; AD04875; AD04876; AD04881; AD04882; AD04883; AD04884; AD04885; AD04962; AD04963; AD04981; AD04982; AD04983; AD05069; AD05070; AD05071; AD05072; AD05073; AD05074; AD05075; AD05076; AD05077; AD05078; AD05147; AD05148; AD05149; AD05164; or AD05165~~

~~55. The RNAi agent of claims 51-54, wherein the substantial identity is exactly, at least, or about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.~~

~~56. The RNAi agent of any of claims 51-54, wherein the substantial identity is at least, or about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.~~

~~57. The RNAi agent of any of claims 51-54, wherein the substantial identity is about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.~~

~~58. The RNAi agent of any of claims 51-54, wherein the substantial identity is at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.~~

~~59. A composition comprising the RNAi agent of any of claims 51-58.~~

~~60. A composition comprising at least two RNAi agents of any of claims 51-58.~~

~~61. The RNAi agent of any of claims 1-9 or 51-58, wherein the RNAi agent comprises at least one overhang.~~

~~62. The RNAi agent of any of claim 61, wherein the RNAi agent comprises an overhang at the 3′ end of the antisense strand.~~

~~63. The RNAi agent of claim 62, wherein the RNAi agent comprises an overhang at the 3′ end of the antisense strand and the 3′ end of the sense strand.~~

~~64. The RNAi agent of any of claims 1-9 or 51-58, wherein the RNAi agent comprises one or two blunt ends.~~

~~65. The RNAi agent of any of claims 1-9 or 51-58, wherein the RNAi agent comprises one or two frayed ends.~~

~~66. The RNAi agent of any of claims 1-9, 51-58, or 61-65, wherein the sense strand comprises at least one inverted abasic nucleoside.~~

CLAIMS

1. An RNAi agent comprising a sense strand comprising a nucleobase sequence according to any one of SEQ ID NO: 302, 282-284, 286-290, 295-297, 300, 306-315, and 319-321, and an antisense strand at least partially complementary to the sense strand.

2. The RNAi agent of claim 1, wherein the antisense strand comprises a nucleobase sequence according to any one of SEQ ID NO: 152, 155-160, 165-171, 174-177, and 179-181.

3. The RNAi agent of claim 1 or 2, wherein the sense strand comprises a nucleotide sequence according to any one of SEQ ID NO: 204-206, 208-212, 219-223, 226, 229, 234-247, 252-255, and 273.

4. The RNAi agent of any one of claims 1-3, wherein the sense strand has a structure of any one of SEQ ID NO: 204-206, 208-212, 219-223, 226, 229, 234-247, 252-255, and 273.

5. The RNAi agent of any one of claims 1-4, wherein the antisense strand comprises a nucleotide sequence according to any one of SEQ ID NO: 72-76, 78, 79, 88-92, 98-100, 108-124, and 126-130.

6. The RNAi agent of any one of claims 1-5, wherein the antisense strand has a structure of any one of SEQ ID NO: 72-76, 78, 79, 88-92, 98-100, and 108-124, 126-130.

7. The RNAi agent of any one of claims 1-6, wherein the RNAi agent comprises an antisense strand and a sense strand having modified nucleotide sequences, the RNAi agent having the duplex structure of AD04001 (SEQ ID NO: 72 and SEQ ID NO: 204); AD04002 (SEQ ID NO: 73 and SEQ ID NO: 204); AD04003 (SEQ ID NO: 74 and SEQ ID NO: 205); AD04004 (SEQ ID NO: 72 and SEQ ID NO: 206); AD04005 (SEQ ID NO: 75 and SEQ ID NO: 212); AD04008 (SEQ ID NO: 78 and SEQ ID NO: 208); AD04009 (SEQ ID NO: 76 and SEQ ID NO: 209); AD04010 (SEQ ID NO: 79 and SEQ ID NO: 211); AD04422 (SEQ

ID NO: 74 and SEQ ID NO: 219); AD04423 (SEQ ID NO: 88 and SEQ ID NO: 205); AD04425 (SEQ ID NO: 89 and SEQ ID NO: 20); AD04426 (SEQ ID NO: 90 and SEQ ID NO: 221); AD04427 (SEQ ID NO: 90 and SEQ ID NO: 222); AD04428 (SEQ ID NO: 91 and SEQ ID NO: 221); AD04429 (SEQ ID NO: 91 and SEQ ID NO: 222); AD04430 (SEQ ID NO: 92 and SEQ ID NO: 223); AD04438 (SEQ ID NO: 98 and SEQ ID NO: 226); AD04439 (SEQ ID NO: 99 and SEQ ID NO: 226); AD04511 (SEQ ID NO: 100 and SEQ ID NO: 229); AD04581 (SEQ ID NO: 108 and SEQ ID NO: 211); AD04583 (SEQ ID NO: 109 and SEQ ID NO: 234); AD04584 (SEQ ID NO: 110 and SEQ ID NO: 234); AD04585 (SEQ ID NO: 111 and SEQ ID NO: 235); AD04586 (SEQ ID NO: 112 and SEQ ID NO: 234); AD04587 (SEQ ID NO: 109 and SEQ ID NO: 236); AD04588 (SEQ ID NO: 110 and SEQ ID NO: 237); AD04590 (SEQ ID NO: 113 and SEQ ID NO: 211); AD04591 (SEQ ID NO: 108 and SEQ ID NO: 238); AD04592(SEQ ID NO: 74 and SEQ ID NO: 239); AD04593 (SEQ ID NO: 114 and SEQ ID NO: 240); AD04594 (SEQ ID NO: 115 and SEQ ID NO: 240); AD04595 (SEQ ID NO: 116 and SEQ ID NO: 241); AD04596 (SEQ ID NO: 117 and SEQ ID NO: 241; AD04597 (SEQ ID NO: 114 and SEQ ID NO: 242); AD04598 (SEQ ID NO: 115 and SEQ ID NO: 243); AD04599 (SEQ ID NO: 118 and SEQ ID NO: 220); AD04734 (SEQ ID NO: 119 and SEQ ID NO: 235); AD04771 (SEQ ID NO: 120 and SEQ ID NO: 244); AD04772 (SEQ ID NO: 121 and SEQ ID NO: 245); AD04773 (SEQ ID NO: 122 and SEQ ID NO: 244); AD04774 (SEQ ID NO: 123 and SEQ ID NO: 246); AD04775 (SEQ ID NO: 123 and SEQ ID NO: 247); AD04822 (SEQ ID NO: 124 and SEQ ID NO: 244); AD04872 (SEQ ID NO: 126 and SEQ ID NO: 252); AD04873 (SEQ ID NO: 127 and SEQ ID NO: 252); AD04874 (SEQ ID NO: 128 and SEQ ID NO: 253); AD04875 (SEQ ID NO: 129 and SEQ ID NO: 254); AD04876 (SEQ ID NO: 130 and SEQ ID NO: 255); AD04962 (SEQ ID NO: 111 and SEQ ID NO: 244) or AD05164 (SEQ ID NO: 126 and SEQ ID NO: 273).

8. An RNAi agent comprising an antisense strand comprising a nucleobase sequence according to any one of SEQ ID NO: 171, 152, 155-160, 165-170, and 174-181, and a sense strand at least partially complementary to the antisense sense strand.

9. The RNAi agent of claim 8, wherein the sense strand comprises a nucleobase sequence according to any one of SEQ ID NO: 282-287, 289, 290, 294-302, 306-315, and 318-321.

10. The RNAi agent of claim 8 or 9, wherein the antisense strand comprises a nucleotide sequence according to any one of SEQ ID NO: 65, 72-79, 88-100, and 108-130.

11. The RNAi agent of any one of claims 8-10, wherein the antisense strand has a structure of any one of SEQ ID NO: 65, 72-79, 88-100, and 108-130.

12. The RNAi agent of any one of claims 8-11, wherein the sense strand comprises a nucleotide sequence according to any one of SEQ ID NO: 204-209, 211, 212, 219-229, 234-248, 251-255, and 273.

13. The RNAi agent of any one of claims 7-12, wherein the sense strand has a structure of any one of SEQ ID NO: 204-209, 211, 212, 219-229, 234-248, 251-255, and 273.

14. The RNAi agent of any one of claims 7-13, wherein the RNAi agent comprises an antisense strand and a sense strand having modified nucleotide sequences, the RNAi agent having the duplex structure of AD04001 (SEQ ID NO: 72 and SEQ ID NO: 204); AD04002 (SEQ ID NO: 73 and SEQ ID NO: 204); AD04003 (SEQ ID NO: 74 and SEQ ID NO: 205); AD04004 (SEQ ID NO: 72 and SEQ ID NO: 206); AD04005 (SEQ ID NO: 75 and SEQ ID NO: 212); AD04006 (SEQ ID NO: 76 and SEQ ID NO: 207); AD04007 (SEQ ID NO: 77 and SEQ ID NO: 207); AD04008 (SEQ ID NO: 78 and SEQ ID NO: 208); AD04009 (SEQ ID NO: 76 and SEQ ID NO: 209); AD04010 (SEQ ID NO: 79 and SEQ ID NO: 211); AD04422 (SEQ ID NO: 74 and SEQ ID NO: 219); AD04423 (SEQ ID NO: 88 and SEQ ID NO: 205); AD04425 (SEQ ID NO: 89 and SEQ ID NO: 20); AD04426 (SEQ ID NO: 90 and SEQ ID NO: 221); AD04427 (SEQ ID NO: 90 and SEQ ID NO: 222); AD04428 (SEQ ID NO: 91 and SEQ ID NO: 221); AD04429 (SEQ ID NO: 91 and SEQ ID NO: 222); AD04430 (SEQ ID NO: 92 and SEQ ID NO: 223); AD04431 (SEQ ID NO: 74 and SEQ ID NO: 224); AD04432 (SEQ ID NO: 74 and SEQ ID NO: 225); AD04433 (SEQ ID NO: 93 and SEQ ID NO: 207); AD04434 (SEQ ID NO: 94 and SEQ ID NO: 207); AD04435 (SEQ ID NO: 95 and SEQ ID NO: 207); AD04436 (SEQ ID NO: 97 and SEQ ID NO: 207); AD04437 (SEQ ID NO: 96 and SEQ ID NO: 207); AD04438 (SEQ ID NO: 98 and SEQ ID NO: 226); AD04439 (SEQ ID NO: 99 and SEQ ID NO: 226); AD04440 (SEQ ID NO: 78 and SEQ ID NO: 227); AD04511 (SEQ ID NO: 100 and SEQ ID NO: 229); AD04581 (SEQ ID NO: 108

and SEQ ID NO: 211); AD04583 (SEQ ID NO: 109 and SEQ ID NO: 234); AD04584 (SEQ ID NO: 110 and SEQ ID NO: 234); AD04585 (SEQ ID NO: 111 and SEQ ID NO: 235); AD04586 (SEQ ID NO: 112 and SEQ ID NO: 234); AD04587 (SEQ ID NO: 109 and SEQ ID NO: 236); AD04588 (SEQ ID NO: 110 and SEQ ID NO: 237); AD04590 (SEQ ID NO: 113 and SEQ ID NO: 211); AD04591 (SEQ ID NO: 108 and SEQ ID NO: 238); AD04592(SEQ ID NO: 74 and SEQ ID NO: 239); AD04593 (SEQ ID NO: 114 and SEQ ID NO: 240); AD04594 (SEQ ID NO: 115 and SEQ ID NO: 240); AD04595 (SEQ ID NO: 116 and SEQ ID NO: 241); AD04596 (SEQ ID NO: 117 and SEQ ID NO: 241; AD04597 (SEQ ID NO: 114 and SEQ ID NO: 242); AD04598 (SEQ ID NO: 115 and SEQ ID NO: 243); AD04599 (SEQ ID NO: 118 and SEQ ID NO: 220); AD04734 (SEQ ID NO: 119 and SEQ ID NO: 235); AD04771 (SEQ ID NO: 120 and SEQ ID NO: 244); AD04772 (SEQ ID NO: 121 and SEQ ID NO: 245); AD04773 (SEQ ID NO: 122 and SEQ ID NO: 244); AD04774 (SEQ ID NO: 123 and SEQ ID NO: 246); AD04775 (SEQ ID NO: 123 and SEQ ID NO: 247); AD04822 (SEQ ID NO: 124 and SEQ ID NO: 244);AD04871 (SEQ ID NO: 125 and SEQ ID NO: 251); AD04872 (SEQ ID NO: 126 and SEQ ID NO: 252); AD04873 (SEQ ID NO: 127 and SEQ ID NO: 252); AD04874 (SEQ ID NO: 128 and SEQ ID NO: 253); AD04875 (SEQ ID NO: 129 and SEQ ID NO: 254); AD04876 (SEQ ID NO: 130 and SEQ ID NO: 255); AD04962 (SEQ ID NO: 111 and SEQ ID NO: 244) or AD05164 (SEQ ID NO: 126 and SEQ ID NO: 273).

15. The RNAi agent of any one of claims 1-14, wherein the RNAi agent comprises a sense strand linked at the 5' terminal end to NAG37s and having the structure (NAG37)s-(invAb)sguggacuuCfUfCfucaauuuucus(invAb) (SEQ ID NO: 252) and an antisense strand having the structure asGfsasAfaAfuUfgAfgAfgAfaGfuCfcasc (SEQ ID NO: 126) .

16. The RNAi agent of any one of claims 1-15, wherein at least one nucleotide of the sense strand and/or at least one nucleotide of the antisense strand of the RNAi agent is a modified nucleotide and/or has a modified internucleoside linkage.

17. The RNAi agent of any one of claims 1-16, wherein all or substantially all of the nucleotides in the sense strand of the RNAi agent are modified nucleotides.

18. The RNAi agent of any one of claims 1-17, wherein all or substantially all of the nucleotides in the antisense strand of the RNAi agent are modified nucleotides.

19. The RNAi agent of any one of claims 1-18, wherein the sense strand and the antisense strand are each 17 to 30 nucleotides in length.

20. The RNAi agent of any of claims 1-19, wherein the RNAi agent is conjugated to a targeting ligand.

21. The RNAi agent of claim 20, wherein the targeting ligand comprises N-acetyl-galactosamine.

22. The RNAi agent of claim 21, wherein the targeting ligand is (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), or (NAG39)s.

23. The RNAi agent of any one of claims 20-22, wherein the targeting ligand is conjugated to the sense strand of the RNAi agent.

24. The RNAi agent of any one of claims 20-23, wherein the targeting ligand is conjugated to the antisense strand of the RNAi agent.

25. The RNAi agent of any one of claims 1-24, wherein the RNAi agent is in a salt form.

26. The RNAi agent of any one of claims 1-25, wherein the RNAi agent is in a sodium salt form.

27. The RNAi agent of any one of claims 1-26, wherein the RNAi agent is in a sodium salt form dissolved in an aqueous solution.

28. A method of making the RNAi agent of any one of claims 1-27, comprising:
synthesizing the sense strand of the RNAi agent,
synthesizing the antisense strand of the RNAi agent, and
annealing the sense and antisense strands to make the RNAi agent.

29. A composition comprising the RNAi agent of any one of claims 1-27, further comprising a pharmaceutically acceptable excipient.

30. The RNAi agent of any one of claims 1-27 or the composition of claim 29, for use in a method for inhibiting expression of a Hepatitis B Virus gene in a subject.

31. The RNAi agent of any one of claims 1-27 or the composition of claim 29, for use in a treatment of an HBV infection and/or a disease, disorder, or condition associated with an HBV infection in a subject.

32. The RNAi agent of any one of claims 1-27 or the composition of claim 29, for use in a treatment of a chronic HBV infection.

33. The RNAi agent of any one of claims 1-27 or the composition of claim 29, for use in a treatment of a chronic Hepatitis D virus (HDV) infection.

34. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is a chronic liver disease or disorder, liver inflammation, a fibrotic condition, a proliferative disorder, hepatocellular carcinoma, Hepatitis D virus infection, or acute HBV infection.

35. The RNAi agent or composition of claims 31 or 34, wherein the subject has at least one of Hepatitis D Virus (HDV) and Human Immunodeficiency Virus (HIV).

36. The RNAi agent or composition of claim 35, wherein the subject is infected with HBV and at least one of HDV or HIV.

37. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is a chronic liver disease or disorder.

38. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is liver inflammation.

39. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is a fibrotic condition.

40. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is a proliferative disorder.

41. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is hepatocellular carcinoma.

42. The RNAi agent or composition of claim 31, wherein the disease, disorder, or condition associated with HBV infection is an (HDV) infection.

43. The RNAi agent or composition of claim 42, wherein the HDV infection is a chronic HDV infection.